Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10338925 | 0.87 | GPR174 (0.58) | GPR174TP53 | |
| SCHEMBL21430441 | 0.82 | TAAR1 (0.50) | LTA4HGPR174 | |
| SCHEMBL6288038 | 0.81 | GPR174 (0.53) | LTA4HGPR174GAARAB9ATP53 | |
| SCHEMBL5931918 | 0.81 | GPR174 (0.53) | GPR174GAARAB9ATP53TSHR | |
| SCHEMBL4661089 | 0.81 | ALDH1A1 (0.51) | PLA2G4AGPR174 | |
| SCHEMBL12035980 | 0.80 | RAB9A (0.49) | GPR174RAB9A | |
| SCHEMBL5033226 | 0.80 | GAA (0.56) | LTA4HNR5A1PLA2G4BGAARAB9A | |
| SCHEMBL26850 | 0.80 | LTA4H (0.70) | LTA4HNR5A1GAARAB9ATP53 | |
| SCHEMBL8161826 | 0.79 | WDR5 (0.57) | GPR174GAA | |
| SCHEMBL8388308 | 0.79 | GPR174 (0.51) | LTA4HNR5A1GPR174TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | NOX5, NQO2, SIRT5 | LTA4H 1294/4885NR5A1 4572/4885PLA2G4B 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.